Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.

ABSTRACT:

Background

Novel systemic therapies have improved response rates and survival in metastatic renal cell cancer (mRCC) and are considered standard of care for this entity. However, complete remission (CR) is rare and often oligoprogression is observed. Here, we analyse the role of surgery for oligoprogressive lesions in mRCC.

Methods

We retrospectively analyzed all patients who underwent surgery for thoracic oligoprogressive lesions of mRCC after receiving systemic therapy including immunotherapy, tyrosine kinase inhibitors (TKI), and/or multikinase inhibitors at our institution between 2007 and 2021 regarding treatment modalities, progression-free survival (PFS) and overall survival (OS).

Results

Ten patients with oligoprogressive mRCC were included. The median interva

SUBMITTER: Le UT 

PROVIDER: S-EPMC10089849 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature